Skip to main content

Table 2 Baseline characteristics according to the primary endpoint

From: Triglyceride-glucose index for predicting repeat revascularization and in-stent restenosis in patients with chronic coronary syndrome undergoing percutaneous coronary intervention

Variable

No such events (n = 866)

Primary endpoint (n = 548)

P-value

Demographics

 Age (years)

58.21 ± 9.35

57.76 ± 9.31

0.374

 Male sex, n (%)

668 (77.14)

435 (79.38)

0.354

 BMI (kg/m2)

25.64 (23.80, 27.64)

25.95 (24.22, 28.29)

0.004

Risk factors

 Cigarette smoking, n (%)

521 (60.16)

337 (61.50)

0.657

 Diabetes, n (%)

329 (37.99)

268 (48.91)

< 0.001

 Hypertension, n (%)

550 (63.51)

356 (64.96)

0.619

 Dyslipidemia, n (%)

864 (99.77)

546 (99.64)

1

 Previous MI, n (%)

104 (12.01)

103 (18.80)

0.001

 Previous stroke, n (%)

96 (11.09)

65 (11.86)

0.718

 Previous PCI, n (%)

198 (22.86)

198 (36.13)

< 0.001

 PAD, n (%)

120 (13.86)

74 (13.50)

0.913

 Family history of CAD, n (%)

168 (19.40)

92 (16.79)

0.244

Clinical presentations

 Multi-vessel CAD, n (%)

652 (75.29)

488 (89.05)

< 0.001

 LVEF (%)

64 (61, 66)

64 (60, 66)

0.010

Laboratory measurements

 TC (mmol/L)

4.02 ± 1.03

4.10 ± 1.06

0.159

 LDL-C (mmol/L)

2.38 ± 0.83

2.47 ± 0.88

0.049

 HDL-C (mmol/L)

1.11 ± 0.30

1.07 ± 0.29

0.003

 Triglycerides (mmol/L)

1.71 ± 1.22

1.82 ± 1.20

0.129

 FPG (mmol/L)

6.09 ± 1.93

6.57 ± 2.39

< 0.001

 HbA1c (%)

6.24 ± 1.06

6.60 ± 1.36

< 0.001

 Pcr (μmol/L)

81.24 ± 15.59

82.11 ± 20.79

0.370

 eGFR (mL/min per 1.73 m2)

110.43 (97.32, 123.70)

111.88 (95.43, 128.43)

0.309

 NT-proBNP (pg/mL)

156.03 ± 329.01

181.99 ± 343.80

0.156

 hs-CRP (mg/L)

3.83 ± 5.01

4.40 ± 7.15

0.079

Medications at discharge

 DAPT, n (%)

859 (99.19)

545 (99.45)

0.807

 Statins, n (%)

849 (98.04)

537 (97.99)

1.000

 Dual-lipid lowering therapy, n (%)

36 (4.16)

26 (4.74)

0.695

 ACEI/ARBs, n (%)

414 (47.81)

293 (53.47)

0.043

 β-Blockers

697 (80.48)

486 (88.69)

0.0001

 Insulin, n (%)

69 (7.97)

86 (15.69)

< 0.001

 Oral hypoglycemic drugs, n (%)

202 (23.33)

165 (30.11)

0.006

Angiographic findings

 Restenotic lesions, n (%)

29 (3.35)

44 (8.03)

< 0.001

 Chronic total occlusions, n (%)

94 (10.85)

97 (17.70)

< 0.001

 Lesions > 20 mm long, n (%)

588 (67.90)

412 (75.18)

0.004

 Number of stents

2 (1, 2)

2 (1, 3)

< 0.001

 Length of stent (mm)

26.50 (16.00, 40.00)

30.00 (20.00, 50.00)

< 0.001

 TyG index

8.80 (8.45, 9.20)

8.90 (8.55, 9.34)

< 0.001

TyG tertiles

0.001

 T1, n (%)

316 (67.67)

151 (32.33)

 

 T2, n (%)

279 (59.87)

187 (40.13)

 

 T3, n (%)

271 (56.34)

210 (43.66)

 
  1. ACEI angiotensin-converting enzyme inhibitor, ARBs angiotensin receptor blockers, BMI body mass index, CAD coronary artery disease, DAPT dual antiplatelet therapy, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, HDL-C high-density lipoprotein-cholesterol, HbA1c glycated hemoglobin A1c, hs-CRP hypersensitive C-reactive protein, LVEF left ventricular ejection fraction, LDL-C low-density lipoprotein-cholesterol, MI myocardial infarction, NT-proBNP N-terminal pro-B-type natriuretic peptide, PCI percutaneous coronary intervention, PAD peripheral arterial disease, Pcr plasma creatine, TC total cholesterol, TyG triglyceride-glucose
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840